SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses
Anthos Christofides(Beth Israel Deaconess Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Sasitorn Yenyuwadee(Beth Israel Deaconess Medical Center), Louis Boon, Carol Cao(Beth Israel Deaconess Medical Center), Mohamed A. A. Mahmoud(Ain Shams University), Rinku Pal(Beth Israel Deaconess Medical Center), John M. Asara(Beth Israel Deaconess Medical Center), Ioannis S. Vlachos(Broad Institute), Natalia M. Tijaro-Ovalle(Beth Israel Deaconess Medical Center), Konstantinos Aliazis(Beth Israel Deaconess Medical Center), Halil‐Ibrahim Aksoylar(Beth Israel Deaconess Medical Center), Xanthi-Lida Katopodi(Beth Israel Deaconess Medical Center), Nikolaos Patsoukis(Beth Israel Deaconess Medical Center), Laura Strauss(AVEO Oncology (United States)), Dimitra Karagkouni(University of Thessaly)
Cited by 85
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|2.9k
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
|Cell|2012|2k
DIANA-miRPath v3.0: deciphering microRNA function with experimental support
|Nucleic Acids Research|2015|1.8k
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
|Science|2019|1.4k
DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA–gene interactions
|Nucleic Acids Research|2017|1.2k